Press release
MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
Multiple Posters Highlight the Breadth of Company’s Novel Genetic Medicine and Cell Therapy Platforms LONDON and NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) --
About this update from Meiragtx Holdings Plc
[{"type":"text","content":"Multiple Posters Highlight the Breadth of Company’s Novel Genetic Medicine and Cell Therapy Platforms\nLONDON and NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the Company will exhibit two posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress, which is being held from October 7-10, 2025, in Seville, Spain. The posters are available on the Posters and Publications page of the Company’s website. The details of the poster presentations are as follows: Poster Number: P0089Abstract Title: Novel AAV Capsids for Intravitreal Delivery Developed by Directed Evolution in Non-human Primate Eyes and Validated in Human Retinal OrganoidsPoster Session: Wednesday 8 October from 14:00 to 15:30 CESTAbstract:We performed an in vivo directed evolution capsid screen in non-human primates to identify novel capsids that target the back of the eye. This involved administering a diverse library of AAV capsid variants intravitreally into the eyes of NHPs. The library was constructed by generating a variety of AAV capsid variants through the insertion of random peptides at a specific site in the capsid. Specifically, a 7-mer peptide display library based on AAV2 was created, with a 7-mer peptide inserted at amino acid 588, flanked by a 5' AAA linker and a 3' AA linker. After administration, the fovea was excised, and retinal cells were harvested. By excluding the fovea, which most capsids readily transduce, we aimed to identify capsids with a broader transduction profile, extending to the perimacular region and beyond. Viral genomes were recovered and sequenced to identify the most efficient variants. By analysing the recovered viral genomes, we identified the top-performing capsids for further development. From a library of ~ 1E7 variants, the top-performing capsids were selected. These candidates were validated and compared head-to-head against AAV2.7m8 and the parental AAV2 in our human retinal organoid platform using live cell imaging, flow cytometry, histology, and single-cell RNA sequencing. We identified variants with significantly higher transduction efficiency compared to the parental serotype, AAV2, and AAV2.7m8. Deep transcriptional profiling using single-cell RNA sequencing demonstrated over 2-...